Chromosome Count and Prenatal Diagnosis of Chromosomal Abnormalities
In prenatal medicine, evaluating the fetal chromosome count and structural integrity is a foundational step in ensuring a healthy pregnancy. Among both numerical and structural chromosomal abnormalities, the most frequently encountered condition is Down syndrome. This genetic condition is caused by the presence of a third copy of chromosome 21, medically referred to as Trisomy 21.
During routine prenatal care, a detailed ultrasound examination between the 18th and 23rd weeks is used to search for specific anatomical markers and soft markers that may suggest numerical chromosomal conditions. However, it is vital to understand that a detailed ultrasound is a screening tool, not a definitive diagnostic method for chromosomal disorders.
Screening Tests vs. Definitive Diagnosis
To evaluate the probability of a chromosomal anomaly, clinicians analyze a combination of ultrasound findings and maternal biochemical markers:
First-Trimester Screening (Combined Test): Conducted between weeks 11 and 14, evaluating fetal nuchal translucency (NT) via ultrasound alongside maternal blood markers (PAPP-A and free $\beta$-hCG).
Second-Trimester Screening (Triple or Quad Screen): Conducted between weeks 15 and 20 to measure specific proteins and hormones in the mother’s blood.
While the results from these screening tests can significantly increase or decrease the estimated risk, they only provide a probability. They cannot confirm whether a numerical abnormality actually exists.
The Gold Standard: Invasive Genetic Testing
When screening risks are high or ultrasound markers indicate an issue, definitive confirmation requires analyzing the actual fetal chromosome count and structure. The gold standard for diagnosing these conditions remains invasive prenatal cytogenetic testing, which utilizes fetal cells obtained through two primary procedures:
Chorionic Villus Sampling (CVS): Performed early in pregnancy (weeks 11–14) by sampling placental tissue.
Amniocentesis: Performed after the 16th week by sampling the amniotic fluid.
The harvested fetal cells are cultured and analyzed in a laboratory setting via traditional karyotyping or molecular techniques. This allows geneticists to physically count the chromosomes and inspect their structure under a microscope, providing a definitive, definitive diagnosis regarding trisomies (such as Trisomy 21, 18, or 13) and other structural rearrangements.